# CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

> **NCT04637763** · PHASE1 · RECRUITING · sponsor: **Caribou Biosciences, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Relapsed Non Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- Lymphoma
- B Cell Lymphoma
- B Cell Non-Hodgkin's Lymphoma

## Interventions

- **GENETIC:** CB-010
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT04637763
- **Lead sponsor:** Caribou Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-26
- **Primary completion:** 2025-08
- **Final completion:** 2025-09
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637763, "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04637763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*